Location:
Hyatt Regency Denver at the Colorado Convention Center
650 15th St
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room:
Capitol Ballroom 4-7 (Fourth Floor)
Schedule (MST):
11:45 AM – 12:15 PM – Registration and Lunch Buffet
12:15 PM – 1:45 PM – Educational Program
There is no registration fee for these events. However, preregistration is required as seating is limited.
Faculty:
Kimberly Camp, RN, BSN, MSN, ANP-BC, ONC
Division of Gynecologic Oncology
Duke Cancer Institute
Durham, North Carolina
Ursula A Matulonis, MD
Medical Director and Program Leader
Gynecologic Oncology Program
Associate Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Michele Peetz, FNP-C
Gynecologic Oncology
Phoenix - Biltmore Cancer Center
Phoenix, Arizona
Angeles Alvarez Secord, MD, MHSc
Professor
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
Duke Cancer Institute
Durham, North Carolina
Moderator:
Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Tesaro Inc (via educational grants) during the Oncology Nursing Society’s (ONS) 42nd Annual Congress, May 3-7, 2017 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
MODULE 1: Overview of Ovarian Cancer (OC)
DISCUSSION TOPICS
- Biology of OC and specific histologic and clinical subtypes
- Clinical presentation and staging
- Role of tumor markers (CA-125)
- Frequency and clinical significance of BRCA germline and somatic mutations
- Options for BRCA germline mutation testing: “One-off” versus multiplex assays
- Selection of patients with OC for genetic testing
- “BRCA-like” and other genomic signatures (eg, homologous recombination deficiency)
- Genetic counseling for patients with OC and their family members
MODULE 2: Treatment of OC in the Pre-PARP Era
DISCUSSION TOPICS
- Patient selection for neoadjuvant systemic therapy and choice of neoadjuvant regimen
- Risks and benefits of intraperitoneal chemotherapy; indications for its use in clinical practice
- Supportive management considerations for patients receiving intraperitoneal chemotherapy
- Available data and ongoing Phase III trials with bevacizumab in the setting of primary OC
- Biologic rationale for the use of “maintenance therapy” after chemotherapy
- FDA approval and optimal integration of bevacizumab in combination with chemotherapy followed by maintenance bevacizumab for patients with platinum-sensitive, recurrent epithelial OC
- Efficacy of bevacizumab as monotherapy
- Mechanisms and determinants of platinum resistance
MODULE 3: Integration of PARP Inhibitors into OC Management
DISCUSSION TOPICS
- Mechanism of action of PARP inhibitors; effect of BRCA mutation status on activity
- Similarities and differences among companion diagnostics developed for FDA-approved PARP inhibitors
- Available data with and FDA-approved indications for olaparib, rucaparib and niraparib
- Optimal integration of olaparib, rucaparib and niraparib into the treatment algorithm
- Current role of PARP inhibitors for patients without BRCA mutations
- Dosing and administration of olaparib, rucaparib and niraparib
- Recognition and management of PARP inhibitor side effects (eg, gastrointestinal toxicities, anemia), including dose reduction and discontinuation strategies
- Risk of acute myeloid leukemia/myelodysplastic syndromes for patients receiving PARP inhibitors
- Design, eligibility requirements and major efficacy findings from the Phase III SOLO-2 trial evaluating olaparib as maintenance therapy for platinum-sensitive recurrent OC
- Other PARP inhibitors under development
MODULE 4: Future Directions and New Agents
DISCUSSION TOPICS
- Novel anti-angiogenic strategies in OC, including tyrosine kinase inhibitors (eg, cediranib, nintedanib, trebananib)
- Mechanism of action, early data and side effects and toxicities associated with mirvetuximab soravtansine
- Available safety and efficacy data with anti-PD-1/PD-L1 antibodies in OC
- Other novel agents and strategies under investigation
Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer (OC).
Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:
- Apply existing and emerging research data to the diagnostic, therapeutic and supportive care of patients with OC.
- Demonstrate knowledge of existing guidelines and consensus statements regarding the rationale for genetic counseling/testing for all patients with newly diagnosed OC, regardless of family history.
- Develop an understanding of the initial and long-term treatment of advanced OC considering the role of the anti-VEGF antibody bevacizumab.
- Implement an evidence-based approach to the prevention and amelioration of side effects associated with chemotherapeutic and biologic agents used in the management of OC.
- Appreciate the FDA approvals of olaparib, niraparib and rucaparib for patients with OC, and safely integrate these agents into the clinical care of appropriate individuals.
- Evaluate existing and emerging evidence supporting the use of PARP inhibitors as maintenance therapy for patients with recurrent, platinum-sensitive OC who are responding to platinum-based chemotherapy.
- Develop an understanding of the available efficacy data and toxicity profiles of investigational PARP inhibitors to effectively prioritize clinical trial opportunities for appropriate patients with OC.
- Recall ongoing trials of other investigational approaches and agents in OC, and refer patients and obtain consent for study participation.
Accreditation Statements:
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.5 contact hours is provided by Research To Practice.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity. Your certificate will be mailed to you within 4 to 6 weeks. International attendees, please note: In order for a certificate of completion to be issued, you must provide a valid email address.
ONCC/ILNA Certification Information:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2017/ILNA
Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.
Content Validation and Disclosures:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
Research To Practice staff and external reviewers — The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
Supporters:
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Tesaro Inc.
Hyatt Regency Denver at the Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room:
Capitol Ballroom 4-7 (Fourth Floor)
The Hyatt Regency Denver at the Colorado Convention Center is the host hotel for the 2017 ONS Annual Congress.
Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 6 — Ovarian Cancer. Onsite registration will be open starting at 11:45 AM (MST) on Friday, May 5th.
If you are interested in standing by for seating (day of the program), please visit our registration desk located outside Capitol Ballroom 4-7 on the fourth floor of the Hyatt Regency Denver hotel at the Colorado Convention Center (650 15th St, Denver, CO 80202). You may arrive up to 45 minutes before the program start time and receive a standby ticket.
If seats become available for the program, we will accept standby registration on a first come, first served basis. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.
|
